Registry evaluating the impact of genomic testing on treatment of prostate cancer patients - European Medical Journal

Registry evaluating the impact of genomic testing on treatment of prostate cancer patients

Oncology

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the interim analysis of PROCEDEāˆ’1000, a prospective registry evaluating the impact of ProlarisĀ®, a cell cycle progression (CCP) test, on personalising treatment decisions following biopsy in newly diagnosed patients with prostate cancer.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now